GTG developing a genetic test in the fight against COVID-19
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Dual-listed Genetic Technologies (ASX:GTG | NASDAQ: GENE) is fast-tracking development of a genetic test that will determine if people are at a high risk of contracting COVID-19.
The company is set to commence development of a polygenic risk score (PRS) test to predict an individual’s risk of developing life-threatening complications should they become infected with COVID-19.
Knowing a person’s risk of contracting COVID-19 and complications can have a huge impact on the community and the economy, in terms of saving lives, better utilising medical resources, getting people back to work, and ensuring that those who most need protection are protected properly.
The company anticipate approximately a three-month development timeline for the review of data and the potential design of a predictive risk model and would then seek to obtain CLIA and potentially other approvals of the laboratory derived test.
Once developed, Genetic Technologies’ COVID-19 test will have global application. A vaccine for COVID-19 is expected to still be a long while off, so this genetic test will be another bullet in the armoury to fight the virus until a vaccine arrives.
The diversified molecular diagnostics company has already developed similar genetic tests for breast cancer and colorectal cancer. Its lead products, GeneType for Breast Cancer for non-hereditary breast cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class. It was also involved in the first major study of the human genome.
Genetic Technologies CEO Dr George Muchnicki said "GENE [GTG] has secured a data set of over 1,500 patients who experienced COVID-19 and we intend on leveraging our core expertise in predictive risk modelling, to analyse the early, available genomic and phenotypic data from those COVID-19 patients with a view to developing a comprehensive predictive model to identify those patients most likely to require hospitalisation, should they become infected with the COVID-19 virus."
Dr Richard Allman Chief Scientific Officer said "Our core-strength is in the design and construction of novel risk algorithms for common, complex diseases. We anticipate that the design of a new predictive test will utilise similar concepts to those used in our existing core GeneType risk assessment products.
“We are fast-tracking analysis of the data set we have received and then we are commencing the development process with the aim of having sufficient understanding of that data to develop and validate a prototype test in the shortest time period possible.
“Of course, until we complete that analysis there is no guarantee that the genetic markers we are looking for will provide sufficient statistical evidence to support predictive risk modelling test."
Further to the above, the company provided a market update on 18 May. This included news that a NASDAQ hearing panel granted full extension for continued listing and details of recent Board changes, plus the following updates.
Further validation of the GeneType for breast cancer and colorectal cancer tests
Two R&D studies are nearing completion which provide further important validation data supporting the GeneType for breast and colorectal cancer tests.
The results are expected to be submitted for publication in peer-reviewed medical journals in the next quarter. The content of these publications is crucial in driving physician acceptance of our tests.
Importantly, the analyses which are derived from large-scale cohort data, include prospective data analysis and set the stage for progressing our plans to develop clinical utility evidence in support of our reimbursement strategy.
Type-2 Diabetes test progressing
In further positive progress, the company has completed development of a prototype test for Type-2 Diabetes. The Melbourne laboratory is implementing the internal work flows and verification procedures prior to commercial launch.
The test is designed to incorporate a polygenic risk score in combination with a clinical risk algorithm to better predict the risk of developing Type-2 Diabetes.
Consumer Initiated Testing (CIT) platform Agreement Signed
After an extensive search and review the company has signed with its preferred CIT platform provider to enable sales of tests to be initiated directly by consumers in the United States.
The company’s current CLIA and NATA accredited laboratory will be utilised for the provision of tests across its current GeneType for Breast and GeneType for Colo-Rectal cancer and will have the capacity to provide additional tests as they come to market. The Platform is expected to go live within 60 days.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
